Mitochondrial energy metabolism in heart failure: A question of balance

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 547-555

  Huss, Janice M ^a   Kelly, Daniel P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENINE NUCLEOTIDE TRANSLOCASE; FIBRIC ACID DERIVATIVE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; UNCLASSIFIED DRUG;

BIOENERGY; DRUG ACTIVITY; FATTY ACID OXIDATION; GENE EXPRESSION PROFILING; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 14644425217     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24405     Document Type: Review

References (125)

1. Stanley, W.C., and Chandler, M.P. 2002. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail. Rev. 7:115-130.
2. Taegtmeyer, H. 1994. Energy metabolism of the heart: from basic concepts to clinical applications. Curr. Probl. Cardiol 19:59-113.
3. Bing, R.J., Siegel, A., Ungar, I., and Gilbert, M. 1954. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am. J. Med. 16:504-515.
4. Shipp J.C., Opie, L.H., and Challoner, D. 1961. Fatty acid and glucose metabolism in the perfused heart. Nature. 189:1018-1019.
5. 14C labelled substrates in humans. J. Clin. Invest. 79:359-366.
6. Kelly, D.P., and Scarpulla, R.C. 2004. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 18:357-368.
7. Anderson, S., et al. 1981. Sequence and organization of the human mitochondrial genome. Nature. 290:457-465.
8. Puigserver, P., et al. 1998. A cold-inducible coactivacor of nuclear receptors linked to adaptive thermogenesis. Cell. 92:829-839.
9. Andersson, U., and Scarpulla, R.C. 2001. PGC-1-related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor-1-dependent transcription in mammalian celis. Mol. Cell. Biol. 21:3738-3749.
10. Lin, J., Puigserver, P., Donovan, J., Tarr, P., and Spiegelman, B.M. 2002. Peroxisome proliferator-accivated receptor γ coactivator 1β (PGC-1β), a novel PGC-1-related transcription coactivator associated with host cell factor. J. Biol. Chem. 277:1645-1648.
11. Kressler, D., Schreiber, S.N., Knutti, D., and Kralli, A. 2002. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J. Biol. Chem. 277:13918-13925.
12. Savagner, F., et al. 2003. PGC-1-related coactivator and targets are upregulated in thyroid oncocytoma. Biochem. Biophys. Res. Commun. 310:779-784.
13. Wu, Z., et al. 1999. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 98:115-124.
14. Kamei, Y., et al. 2003. PPARγ coactivator 1β/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc. Natl. Acad. Sci. U. S. A. 100:12378-12383.
15. St-Pierre, J., et al. 2003. Bioenergetic analysis of pefoxisome proliferator-activated receptor γ coactivators 1α and 1β (PGC-1α and PGC-1β) in muscle cells. J. Biol. Chem. 278:26597-26603.
16. Herzig, S., et al. 2001. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 413:179-183.
17. Rhee, J., et al. 2003. Regulation of hepatic fasting response by PPARγ coactivator-1α (PGC-1α): requirement for hepatocyte nuclear factor 4α in gluconeogenesis. Proc. Natl. Acad. Sci. U. S. A. 100:4012-4017.
18. Michael, L.F., et al. 2001. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. U. S. A. 98:3820-3825.
19. Lehman, J.J., et al. 2000. PPARγ coactivator-1 (PGC-1) promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 106:847-856.
20. Baat, K., et al. 2002. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1α. FASEB J. 16:1879-1886.
21. Puigserver, P., et al. 2001. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARγ coactivator-1. Mol. Cell. 8:971-982.
22. Wu, H., et al. 2002. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science. 296:349-352.
23. Goto, M., et al. 2000. cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats. Biochem. Biophys. Res. Commun. 274:350-354.
24. Huss, J.M., Pinéda Torra, I., Staels, B., Giguère, V., and Kelly, D.P. 2004. ERRα directs PPAR α signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24:9079-9091.
25. Russell, L.K., et al. 2004. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-actived receptor γ coactivator-1α promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ. Res. 94:525-533.
26. Fisher, R.P., Lisowsky, T., Parisi, M.A., and Clayton, D.A. 1992. DNA wrapping and bending by a mitochondrial high mobility group-like transcriptional activator protein. J. Biol. Chem. 267:3358-3367.
27. Garesse, R., and Vallejo, C.G. 2001. Animal mitochondrial biogenesis and function: a regulatory cross-talk between two genomes. Gene. 263:1-16.
28. Larsson, N.-G., et al. 1998. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat. Genet. 18:231-236.
29. Scarpulla, R.C. 2002. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim. Biophys. Acta. 1576:1-14.
30. Virbasius, C.A., Virbasius, J.V., and Scarpulla, R.C. 1993. NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators. Genes Dev. 7:2431-2445.
31. Vega, R.B., Huss, J.M., and Kelly, D.P. 2000. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20:1868-1876.
32. Dressel, U., et al. 2003. The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. 17:2477-2493.
33. Huss, J.M., Kopp, R.P., and Kelly, D.P. 2002. PGC-1α coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-α and -γ. J. Biol. Chem. 277:40265-40274.
34. Schreiber, S.N., Knutti, D., Brogli, K., Uhlmann, T., and Kralli, A. 2003. The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor α (ERRα). J. Biol. Chem. 278:9013-9018.
35. Desvergne, B., and Wahli, W. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20:649-688.
36. Lee, S.S.T., et al. 1995. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15:3012-3022.
37. Watanabe, K., et al. 2000. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity. J. Biol. Chem. 275:22293-22299.
38. Djouadi, F., et al. 1999. The role of the peroxisome proliferator- activated receptor α (PPARα) in the control of cardiac lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids. 60:339-343.
39. Campbell, F.M., et al. 2002. A role for PPARα in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARα are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J. Biol. Chem. 277:4098-4103.
40. Kersten, S., et al. 1999. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103:1489-1498.
41. Leone, T.C., Weinheimer, C.J., and Kelly, D.P. 1999. A critical role for the peroxisome proliferator-activated receptor alpha (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. U. S. A. 96:7473-7478.
42. Gilde, A.J., et al. 2003. PPARα and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 92:518-524.
43. Cheng, L., et al. 2004. Peroxisome proliferator-activated receptor δ activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem. Biophys. Res. Commun. 313:277-286.
44. Cheng, L., et al. 2004. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10:1245-1250.
45. Giguète, V., Yang, N., Segui, P., and Evans, R.M. 1988. Identification of a new class of steroid hormone receptors. Nature. 331:91-94.
46. Heard, D.J., Norbu, P.L., Holloway, J., and Vissing, H. 2000. Human ERRγ, a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult. Mol. Endocrinol. 14:383-392.
47. Hong, H., Yang, L., and Stallcup, M.R. 1999. Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. J. Biol. Chem. 274:22618-22626.
48. Sladek, R., Bader, J.-A., and Giguère, V. 1997. The orphan nuclear receptor estrogen-related receptor α is a transcriptional regulator of the human medium-chain acyl coenzyme a dehydrogenase gene. Mol. Cell. Biol. 17:5400-5409.
49. Hentschke, M., Susens, U., and Borgmeyer, U. 2002. PGC-1 and PERC, coactivators of the estrogen receptor-related receptor gamma. Biochem. Biophys. Res. Commun. 299:872-879.
50. Laganiere, J., et al. 2004. A polymorphic autoregulatory hormone response element in the human estrogen-related receptor α (ERRα) promoter dictates peroxisome proliferator-activated receptor γ coactivator-1α control of ERRa expression. J. Biol. Chem. 279:18504-18510.
51. Mootha, V.K., et al. 2004. ERRa and Gabpa/b specify PGC-1α- dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc. Natl. Acad. Sci. U. S. A. 101:6570-6575.
52. Schreiber, S.N., et al. 2004. The estrogen-related receptor alpha (ERRα) functions in PPARγ coactivator 1α (PGC-1α)- induced mitochondrial biogenesis. Proc. Natl. Acad. Sci. U. S. A. 101:6472-6477.
53. 4-adrenergic receptor on the expression of uncoupling proteins and peroxisome proliferator-activated receptor-γ coactivator-1. Biochem. Biophys. Res. Commun. 261:870-876.
54. Knutti, D., Kressler, D., and Kralli, A. 2001. Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a corepressor. Proc. Natl. Acad. Sci. U. S. A. 98:9713-9718.
55. Fan, M., et al. 2004. Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev. 18:278-289.
56. Barger, P.M., Browning, A.C., Garner, A.N., and Kelly, D.P. 2001. p38 MAP kinase activates PPARα: a potential role in the cardiac metabolic stress response. J. Biol. Chem. 276:44495-44501.
57. Ballal, K., Sekiguchi, K., Nanda, S., and Barger, P. 2004. ERK MAPK regulation of cardiac retinoid X receptor is involved in impaired fatty acid β-oxidation during hypertrophic growth [abstract]. Circulation. 110(Suppl.):946.
58. Nisoli, E., et al. 2003. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 299:896-899.
59. Nisoli, E., Clementi, E., Moncada, S., and Carruba, M.O. 2004. Mitochondrial biogenesis as a cellular signaling framework. Biochem. Pharmacol. 67:1-15.
60. Naya, F.J., et al. 2000. Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J. Biol. Chem. 275:4545-4548.
61. Ryder J.W., Bassel-Duby, R., Olson, E.N., and Zierath, J.R. 2003. Skeletal muscle reprogramming by activation of calcineurin improves insulin action on metabolic pathways. J. Biol. Chem. 278:44298-44304.
62. Handschin, C., Rhee, J., Lin, J., Tam, P.T., and Spiegelman, B.M. 2003. An autoregulatory loop controls peroxisome proliferator-activated receptor γ coactivator 1α expression in muscle. Proc. Natl. Acad. Sci. U. S. A. 100:7111-7116.
63. Eto, Y., et al. 2000. Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation. 101:2134-2137.
64. Molkentin, J.D., et al. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:215-228.
65. Passier, R., et al. 2000. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105:1395-1406.
66. Schaeffer, P.J., et al. 2004. Calcineurin and calcium/ calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiac muscle. J. Biol. Chem. 279:39593-39603.
67. Bishop, S.P., and Altschuld, R.A. 1970. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am. J. Physiol. 218:153-159.
68. Allard, M.F., Schonekess, B.O., Henning, S.L., English, D.R., and Lopaschuk, G.D. 1994. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol. 267:H742-H750.
69. Christe, M.D., and Rodgers, R.L. 1994. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J. Mol. Cell. Cardiol. 26:1371-1375.
70. Taegtmeyer, H., and Overturf, M.L. 1988. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 11:416-426.
71. Massie, B.M., et al. 1995. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation. 91:1814-1823.
72. Sambandam, N., Lopaschuk, G.D., Brownsey, R.W., and Allard, M.F. 2002. Energy metabolism in the hypertrophied heart. Heart Fail. Rev. 7:161-173.
73. Sack, M.N., et al. 1996. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 94:2837-2842.
74. Razeghi, P., et al. 2001. Metabolic gene expressin in fetal and failing human heart. Circulation. 104:2923-2931.
75. Razeghi, P., Young, M.E., Abbasi, S., and Taegtmeyer, H. 2001. Hypoxia in vivo decreases peroxisome proliferator-activated receptor alpha-regulated gene expression in rat heart. Biochem. Biophys. Res. Commun. 287:5-10.
76. Davila-Roman, V.G., et al. 2002. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 40:271-277.
77. de las Fuentes, L., et al. 2003. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertension and in left ventricular dysfunction. Hypertension. 41:83-87.
78. Recchia, F.A., et al. 1998. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ. Res. 83:969-979.
79. Paolisso, G., et al. 1994. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism. 43:174-179.
80. Wallhaus, T.R., et al. 2001. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 103:2441-2446.
81. Chandler, M.P., et al. 2004. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am. J. Physiol. Heart Circ. Physiol. 287:H1538-H1543.
82. Sack, M.N., Disch, D.L., Rockman, H.A., and Kelly, D.P. 1997. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc. Natl. Acad. Sci. U. S. A. 94:6438-6443.
83. Barger, P.M., Brandt, J.M., Leone, T.C., Weinheimer, C.J., and Kelly, D.P. 2000. Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J. Clin. Invest. 105:1723-1730.
84. Lehman, J.J., and Kelly, D.P. 2002. Transcriprional activation of energy metabolic switches in the developing and hypertrophied heart. Clin. Exp. Pharmacol. Physiol. 29:339-345.
85. Barger, P.M., and Kelly, D.P. 2000. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10:238-245.
86. Kanda, H., Nohara, R., Hasegawa, K., Kishimoto, C., and Sasayama, S. 2000. A nuclear complex containing PPARα/RXRα is markedly downregulated in the hypertrophied rat left ventricular myocardium with normal systolic function. Heart Vessels. 15:191-196.
87. Garnier, A., et al. 2003. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J. Physiol. 551:491-501.
88. Huss, J.M., Levy, F.H., and Kelly, D.P. 2001. Hypoxia inhibits the PPARα/RXR gene regulatory pathway in cardiac myocytes. J. Biol. Chem. 276:27605-27612.
89. Osorio, J.C., et al. 2002. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 106:606-612.
90. Tian, R. 2003. Transcriprional regulation of energy substrate metabolism in normal and hypertrophied heart. Curr. Hypertens. Rep. 5:454-458.
91. Wall, S.R., and Lopaschuk, G.D. 1989. Glucose oxidation rates in fatty acid perfused isolated working hearts from diabetic rat. Biochim. Biophys. Acta. 1006:97-103.
92. Saddik, M., and Lopaschuk, G.D. 1994. Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Can. J. Physiol. Pharmocol. 72:1110-1119.
93. Belke, D.D., Larsen, T.S., Gibbs, E.M., and Severson, D.L. 2000. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. 279:E1104-E1113.
94. Neitzel, A.S., Carley, A.N., and Severson, D.L. 2003. Chylomicron and palmitate metabolism by perfused hearts from diabetic mice. Am. J. Physiol. Endocrinol. Metab. 284:E357-E365.
95. Finck, B., et al. 2003. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation of phenotype by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 100:1226-1231.
96. Finck, B., et al. 2002. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109:121-130. doi:10.1172/JCI200214080.
97. Depre, C., et al. 2000. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J. Mol. Cell Cardiol. 32:985-996.
98. Young, M.E., et al. 2001. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor α in the adult rodent heart. FASEB J. 15:833-845.
99. Kelly, D.P., and Strauss, A.W. 1994. Inherited cardiomyopathies. N. Engl. J. Med. 330:913-919.
100. Exil, V.J., et al. 2003. Very-long-chain Acyl-coenzyme A dehydrogenase deficiency in mice. Circ. Res. 93:448-455.
101. Kurtz, D.M., et al. 1998. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc. Natl. Acad. Sci. U. S. A. 95:15592-15597.
102. Schaffer, J.E. 2003. Lipotoxicity: when tissues over-eat. Curr. Opin. Lipidol. 14:281-287.
103. Chiu, H.-C., et al. 2001. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107:813-822.
104. Yagyu, H., et al. 2003. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J. Clin. Invest. 111:419-426. doi:10.1172/JCI200316751.
105. Listenberger, L.L., Ory, D.S., and Schaffer, J.E. 2001. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J. Biol. Chem. 276:14890-14895.
106. deVries, J.E., et al. 1997. Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. J. Lipid Res. 38:1384-1394.
107. Kong, J.Y., and Rabkin, S.W. 2002. Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am. J. Physiol. Heart Circ. Physiol. 282:717-725.
108. Young, M.E., Laws, F.A., Goodwin, G.W., and Taegtmeyer, H. 2001. Reactivation of peroxisome proliferaror-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276:44390-44395.
109. Hopkins, T.A., et al. 2003. Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-α transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 285:H270-H276.
110. Shen, X., et al. 2004. Cardiac mitochondrial damage and biogenesis in a chronic model of type I diabetes. Am. J. Physiol. Endocrinol. Metab. 287:896-905.
111. Ye, G., Metreveli, N.S., Ren, J., and Epstein, P.N. 2003. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes. 52:777-783.
112. Ye, G., et al. 2004. Catalase protect cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes. 53:1336-1343.
113. Liang, Q., et al. 2002. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes. 51:174-181.
114. Wallace, D.C. 1999. Mitochondrial diseases in man and mouse. Science. 283:1482-1488.
115. DiMauro, S., and Schon, E.A. 2001. Mitochondrial DNA mutations in human disease. Am. J. Med. Genet. 106:18-26.
116. Larsson, N.G., and Oldfors, A. 2001. Mitochondrial myopathies. Acta Physiol. Scand. 171:385-393.
117. Kirby, D.M., et al. 2004. NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial comlex I deficiency. J. Clin. Invest. 114:837-845. doi:10.1172/JCI200420683.
118. Li, H., et al. 2000. Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 97:3467-3472.
119. Hansson, A., et al. 2004. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient hearts. Proc. Natl. Acad. Sci. U. S. A. 101:3136-3141.
120. Stepien, G., Torroni, A., Chung, A.B., Hodge, J.A., and Wallace, D.C. 1992. Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation. J. Biol. Chem. 267:14592-14597.
121. Graham, B.H., et al. 1997. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat. Genet. 16:226-234.
122. Murdock, D.G., Boone, B.E., Esposito, L.A., and Wallace, D.C. 1999. Up-regulation of nuclear and mitochondrial genes in the skeletal muscle of mice lacking the heart/muscle isoform of the adenine nucleotide translocator. J. Biol. Chem. 274:14429-14433.
123. Esposito, L.A., Melov, S., Panov, A., Cottrell, B.A., and Wallace, D.C. 1999. Mitochondrial disease in mouse results in increased oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 96:4820-4825.
124. Sano, M., et al. 2002. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat. Med. 8:1310-1317.
125. Sano, M., et al. 2004. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J. 23:3559-3569.